GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Apures Co Ltd (XKRX:149300) » Definitions » Inventories, Finished Goods

Apures Co (XKRX:149300) Inventories, Finished Goods : ₩219.9 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Apures Co Inventories, Finished Goods?

Apures Co's quarterly finished goods declined from Dec. 2021 (₩296.1 Mil) to Dec. 2022 (₩198.8 Mil) but then increased from Dec. 2022 (₩198.8 Mil) to Dec. 2023 (₩219.9 Mil).

Apures Co's annual finished goods declined from Dec. 2021 (₩296.1 Mil) to Dec. 2022 (₩198.8 Mil) but then increased from Dec. 2022 (₩198.8 Mil) to Dec. 2023 (₩219.9 Mil).


Apures Co Inventories, Finished Goods Historical Data

The historical data trend for Apures Co's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apures Co Inventories, Finished Goods Chart

Apures Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.88 225.76 296.08 198.81 219.90

Apures Co Semi-Annual Data
Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only 194.88 225.76 296.08 198.81 219.90

Apures Co Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.


Apures Co (XKRX:149300) Business Description

Traded in Other Exchanges
N/A
Address
44, Hansan-gil, Cheongbuk-eup, Gyeonggi-do, Pyeongtaek-si, KOR, 17792
Apures Co Ltd is a South Korea based company engaged in the development of transgenic animals to support bio heterogeneous long-term commercialization and new drug efficacy research. It has focused its research capabilities on developing transgenic mini pigs based on gene editing technology and somatic cell nuclear transfer technology.

Apures Co (XKRX:149300) Headlines

No Headlines